Development of a novel biologic showing downregulation of immune responses, suppression of bone destruction and retention in the target site.

2017 Fiscal Year Final Research Report

• Project/Area Number: 16K15654
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Orthopaedic surgery
• Research Institution: The University of Tokyo
• Principal Investigator: Honma Masashi 東京大学, 医学部附属病院, 講師 (60401072)
• Project Period (FY): 2016-04-01 – 2018-03-31
• Keywords: 免疫学 / 骨代謝 / シグナル伝達 / 生理活性

Outline of Final Research Achievements

Outcomes of RA treatment are recently improved due to the development of various anti-inflammatory biologics, however; there remains insufficiency from the viewpoint of protection from the bone destruction and the rate of remission induction. In the present study, we constructed a novel biologic; a tandem fusion construct of CTLA-4 extracellular domain, IgG1 Fc domain and anti-RANKL scFv. Experimental treatment of collagen-induced arthritis mice model showed that this construct exhibited stronger suppression of articular inflammation and protection from cartilage and bone destruction compared to the existing biologic abatacept.

Free Research Field

骨軟骨代謝学・リウマチ学